Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) VP Sergio Garcia sold 20,000 shares of the firm’s stock in a transaction dated Monday, October 17th. The shares were sold at an average price of $39.08, for a total transaction of $781,600.00. Following the transaction, the vice president now owns 86,241 shares of the company’s stock, valued at approximately $3,370,298.28. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) traded up 1.03% during mid-day trading on Tuesday, hitting $39.30. 523,547 shares of the stock were exchanged. The firm has a 50-day moving average price of $39.28 and a 200-day moving average price of $32.65. The stock has a market capitalization of $1.56 billion, a P/E ratio of 59.10 and a beta of 0.79. Zeltiq Aesthetics Inc. has a 12-month low of $18.41 and a 12-month high of $41.48.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.07. The firm earned $89.50 million during the quarter, compared to analyst estimates of $79.68 million. Zeltiq Aesthetics had a negative return on equity of 9.90% and a net margin of 9.54%. Zeltiq Aesthetics’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.03 earnings per share. Equities analysts predict that Zeltiq Aesthetics Inc. will post ($0.13) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Zeltiq Aesthetics (NASDAQ:ZLTQ)

Several research firms have recently weighed in on ZLTQ. Maxim Group raised their price objective on shares of Zeltiq Aesthetics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Leerink Swann restated an “outperform” rating and set a $48.00 price objective (up previously from $43.00) on shares of Zeltiq Aesthetics in a research report on Thursday, August 11th. Brean Capital set a $39.00 price objective on shares of Zeltiq Aesthetics and gave the company a “buy” rating in a research report on Tuesday, August 9th. Stifel Nicolaus raised their price objective on shares of Zeltiq Aesthetics from $38.00 to $52.00 and gave the company a “buy” rating in a research report on Wednesday, September 21st. Finally, JPMorgan Chase & Co. restated a “hold” rating and set a $35.00 price objective (up previously from $27.00) on shares of Zeltiq Aesthetics in a research report on Tuesday, August 9th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $39.89.

Hedge funds have recently made changes to their positions in the company. FMR LLC raised its stake in shares of Zeltiq Aesthetics by 45.2% in the second quarter. FMR LLC now owns 4,277,811 shares of the company’s stock worth $116,913,000 after buying an additional 1,332,129 shares during the last quarter. BlackRock Fund Advisors raised its stake in shares of Zeltiq Aesthetics by 9.5% in the second quarter. BlackRock Fund Advisors now owns 2,297,982 shares of the company’s stock worth $62,804,000 after buying an additional 199,946 shares during the last quarter. Point72 Asset Management L.P. raised its stake in shares of Zeltiq Aesthetics by 30.7% in the second quarter. Point72 Asset Management L.P. now owns 2,219,762 shares of the company’s stock worth $60,666,000 after buying an additional 521,462 shares during the last quarter. Aisling Capital LLC raised its stake in shares of Zeltiq Aesthetics by 0.3% in the second quarter. Aisling Capital LLC now owns 2,109,727 shares of the company’s stock worth $57,659,000 after buying an additional 6,199 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Zeltiq Aesthetics by 4.1% in the second quarter. Vanguard Group Inc. now owns 1,569,585 shares of the company’s stock worth $42,897,000 after buying an additional 61,700 shares during the last quarter.

About Zeltiq Aesthetics

ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.

5 Day Chart for NASDAQ:ZLTQ

Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.